Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
1. Novo Nordisk’s Wegovy faces competition from Eli Lilly's Zepbound. 2. CagriSema's Phase 3 trial results did not meet investor expectations. 3. Q4 earnings beat expectations, forecasting 16-24% sales growth. 4. CEO expresses confidence in increasing patient volume and market demand. 5. CagriSema shows potential, with some patients demonstrating rapid weight loss.